Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03799003 · ClinicalTrials.gov registry record · Phase 1
A Study of ASP1951 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT03799003 is a Phase 1 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 119 participants.
The verdict
NCT03799003, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.
Interventions
- DRUG pembrolizumab
- DRUG ASP1951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03799003
The ClinicalTrials.gov registry entry for NCT03799003 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT03799003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03799003 about?
NCT03799003 is a clinical study titled "A Study of ASP1951 in Subjects With Advanced Solid Tumors". The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP19...
What is the current status of trial NCT03799003?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2019-01-14. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03799003?
The interventions under investigation include: pembrolizumab (DRUG), ASP1951 (DRUG).
Who is sponsoring clinical trial NCT03799003?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.